| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 62.3 | 60.7 |
| Gross profit | 39.9 | 37.3 |
| Profit before tax | 6.0 | 2.0 |
| Net income | 4.3 | 2.5 |
| EPS (diluted, $ a share) | $0.75 | $0.45 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +75.3% |
|---|---|
| Revenue, year on year | +2.6% |
| Gross margin | 64.0% |
| Operating margin | 13.5% |
10-Q filed with the SEC, NASDAQ: MLAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Mesa Laboratories Inc: key numbers
- Share price
- $134.09Close, Nov 16
- Market cap
- $754M
- Shares outstanding
- 5.62MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Industrial Instruments For Measurement, Display, and ControlSIC 3823
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mesa Laboratories Inc
All →Mesa Laboratories Earnings Call: Key Takeaways
Mesa Labs is restructuring Clinical Genomics to prioritize profitability over scale while providing its first-ever full-year guidance and initiating a $40 million share repurchase program.
Mesa Laboratories Financial Results
Mesa Laboratories reported second quarter fiscal 2027 results with revenues increasing 2.6% to $62.3 million and net income rising 75.3% to $4.3 million. The company issued full-year fiscal 2027 guidance for the first time, forecasting revenues between $250 million and $255 million. Performance was driven by record revenues in the Sterilization and Disinfection Control division, partially offset by export-control delays in the Biopharmaceutical Development segment.
- Term
- Q2 2027
“Our second quarter showed the progress we are making and the work that remains. SDC is shipping more reliably on most of its product lines, and the Savings Plan we announced in October is under way. Today we are giving full-year guidance for the first time. We have built it conservatively, on a half-year of data under the changes we have made, because a number that our shareholders can count on is worth more than one that flatters a quarter”
Dr. Siddhartha Kadia, President and CEO
“Second quarter revenues of $62,336 represented 2.6% organic (3.1% constant currency organic) growth, continuing positive organic growth in each quarter of FY27 to date. Growth was driven by SDC and CS, partially offset by BPD, which continued to be impacted by export-control processing delays, and CG. Adjusted EBITDA was 27.8% of revenues versus 23.5% in 2Q26. In the second quarter, we repaid $11,406 of debt and reduced our Total Net Leverage Ratio to 1.75”
John Sakys, Chief Financial Officer
Mesa Laboratories Business Update
Mesa Laboratories approved a restructuring program to reduce annualized operating costs by approximately $9.3 million, primarily by focusing its Clinical Genomics division on pharmacogenomics and oncology. The plan involves eliminating 40 positions (6% of the workforce) and exiting a facility in Hamburg, Germany, with an estimated $2.6 million to $3.4 million in pre-tax charges.